GSK plc Sponsored ADR (GSK)
GSK’s RSV vaccine gets greenlight in Japan
GSK PLC (LSE:GSK, NYSE:GSK) has announced that Japan’s Ministry of Health, Labour and Welfare has approved its RSV vaccine, Arexvy, for use in adults aged 50-59 at increased risk of severe RSV-related outcomes. The vaccine was previously approved in Japan for individuals aged 60 and older. "This approval reflects our ambition to protect people at increased risk from the severe consequences of RSV infection,” GSK chief scientific officer Tony Wood said in a statement. “Adults aged 50-59 with certain underlying medical conditions can face debilitating consequences from RSV, so we are pleased to offer those in Japan a vaccine for the first time." Respiratory Syncytial Virus (RSV) is a common virus that can cause severe illness in adults with underlying health conditions such as COPD, asthma, and chronic heart failure. Happy Creek Minerals CEO Jason Bahnsen joined Steve Darling from Proactive to share exciting findings from the company’s 2024 reconnaissance fieldwork on its Silverboss and Hen-DL properties in south-central British Columbia. During the field season, the company collected 56 rock, 113 soil, and 17 stream sediment samples, which revealed anomalous copper, gold, and silver values, underscoring the potential for discovering significant mineral deposits on both projects. On the Hen-DL property, a standout discovery was a large boulder near the Eureka thrust fault, yielding highly anomalous results for nickel, chromium, cobalt, and platinum. This boulder is believed to originate from a relatively unexplored area of the property, signaling the potential of the mineralized system. Similarly, on the DL property, the team identified a large gabbro-pyroxenite rock boulder, which also exhibited highly anomalous assay results for nickel, chromium, cobalt, and platinum, further pointing to mineralization associated with the Eureka fault area. “These results validate the geological potential of our properties,” said Bahnsen. “We are excited about the discoveries made during the 2024 field season and the opportunities they present for advancing exploration on both the Silverboss and Hen-DL projects.” The company plans to further investigate the source of these boulders and the mineralized zones, emphasizing the significant exploration potential within these promising British Columbia assets.
GSK's RSV vaccine gets Japan approval for adults aged 50 to 59
GSK said on Friday that its respiratory syncytial virus (RSV) vaccine has received approval in Japan for expanded use in adults aged between 50 and 59, who are at increased risk of severe RSV disease.
GSK Drug for Rare Disease-Related Itch Meets Goal in Phase III Study
The GLISTEN study evaluating GSK's candidate, linerixibat, for treating cholestatic pruritus related to primary biliary cholangitis meets the primary endpoint.
GSK share price is imploding: is it safe to buy the dip?
The GSK share price has been in a strong freefall after peaking at 1,785p in September. Most recently, the GSK stock retreated for five consecutive weeks and reached its lowest level since October last year.
GSK trial shows promising results for treatment of persistent itch in rare liver disease
GSK PLC (LSE:GSK, NYSE:GSK)has reported positive results from its phase III trial of linerixibat, a drug being tested to treat relentless itching caused by primary biliary cholangitis (PBC). PBC is a rare autoimmune disease that damages the bile ducts and can lead to liver failure.
GSK drug meets main goal in late-stage study to treat relentless itch
British drugmaker GSK said on Tuesday its experimental therapy, linerixibat, met its main goal in a late-stage trial to treat patients with a so-called relentless itch associated with a rare autoimmune liver disease.
Medicus Pharma unveils ex-GSK and Pfizer senior as chief medical officer
Medicus Pharma (TSX-V:MDCX, NASDAQ:MDCX) Ltd has announced the appointment of Faisal Mehmud, formerly of GSK PLC (LSE:GSK, NYSE:GSK) and Pfizer Inc (NYSE:PFE, ETR:PFE), as chief medical officer. Mehmud has over 20 years of experience as a senior medical executive in clinical development, medical affairs and drug safety, Medicus said on Monday.
As Drug Maker Stocks Fall, Pressure Builds On PhRMA To Derail RFK, Jr.
Stocks of major drug makers and biotech companies tumbled in trading late this week after President-elect Donald Trump announced that he wants vaccine skeptic Robert F. Kennedy Jr. to lead the U.S. Department of Health and Human Services.
GSK plc (GSK) Guggenheim's Inaugural Healthcare Innovation Conference (Transcript)
GSK plc (NYSE:GSK ) Guggenheim's Inaugural Healthcare Innovation Conference November 12, 2024 2:00 PM ET Company Participants Emma Walmsley - Chief Executive Officer Conference Call Participants Seamus Fernandez - Guggenheim Seamus Fernandez I'm absolutely thrilled that this we're clearly going to have the best conversation in the fireside chat that we've had so far. Incredibly pleased to have Emma Walmsley here.
GSK at two-year low, drug firms hit on vaccine sceptic US health appointment
GSK PLC (LSE:GSK, NYSE:GSK) shares fell to a two-year low as AstraZeneca PLC also came under pressure on Friday after Robert F Kennedy Junior was announced as US health secretary. President-elect Donald Trump said Thursday that Kennedy, who has previously voiced anti-vax opinions, would be appointed.
GSK going nowhere while key vaccines struggle, says US bank
GSK PLC (LSE:GSK, NYSE:GSK) looks undervalued, but the problem is that there is nothing on the horizon to change that perception according to analysts at US bank Jefferies. Downgrading its investment rating to 'hold', Jefferies said that the spate of good news - favourable Zantac settlement, robust performance of Specialty, and pipeline successes – has been swamped by concerns about vaccines Shingrix (Shingles) and Arexvy (RSV).
CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2024 and Provides Business Update
Strengthened Cash, Strategic Refocus and Pipeline Progress Define Transformative Quarter €400 million upfront payment from restructured GSK collaboration reflected in financials, cash position increased to €551 million; expected cash runway re-affirmed into 2028 CVGBM Phase 1 glioblastoma study showed 77% of patients with antigen-specific T-cell responses; data presented at ESMO, SITC and SNO New off-the-shelf program for squamous non-small cell lung cancer started, expected to enter Phase 1 in H2 2025 New preclinical prophylactic vaccine program for urinary tract infections initiated, supported by positive preclinical data versus protein-based vaccines Positive Phase 2 data from seasonal influenza program licensed to GSK demonstrated strong immune responses against challenging influenza B as well as A strains; program progressing to Phase 3, which will be associated with significant milestone payment Corporate redesign on track with 30% workforce reduction, expected to yield significant annual cost savings from 2025 onwards and increase operational agility Appointment of seasoned industry executive Axel Malkomes as new CFO effective November 11, enhancing financial leadership and strategic execution CureVac to host conference call and webcast today at 9 a.m. EST / 3 p.m.
